metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-56 LOW ROLE OF NON-INVASIVE FIBROSIS ASSESSMENT USING FIB-4 AND APRI IN PATIEN...
Información de la revista
Vol. 24. Núm. S1.
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
(septiembre 2021)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 24. Núm. S1.
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
(septiembre 2021)
Open Access
P-56 LOW ROLE OF NON-INVASIVE FIBROSIS ASSESSMENT USING FIB-4 AND APRI IN PATIENTS WITH AUTOIMMUNE HEPATITIS
Visitas
470
Aline Lamaison1, Javier Troncoso1, Pablo Villafranca1, Marcel Bonilla1, Maximo Cattaneo2, Laura Carreño3, Jaime Poniachik2, Alvaro Urzúa2
1 Escuela de Medicina, Universidad de Chile, Santiago, Chile
2 Sección de Gastroenterología, Departamento de Medicina Interna, Hospital Clínico Universidad de Chile, Santiago, Chile
3 Departamento de Anatomía Patológica, Hospital Clínico Universidad de Chile, Santiago, Chile
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Suplemento especial
Este artículo forma parte de:
Vol. 24. Núm S1

Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)

Más datos
Introduction

The evaluation with non-invasive tests (NIT) of liver fibrosis is a more accessible method to estimate risk in patients with liver disease. The APRI and FIB-4 are scores that use easily accessible laboratory variables. They have been validated mainly in viral hepatitis and non-alcoholic fatty liver (NAFLD), but their usefulness in autoimmune hepatitis (HAI) has been little studied.

Objective

To evaluate the usefulness of APRI and FIB-4 in the screening of significant fibrosis (SF) in patients with HAI.

Methods

Observational, cross-sectional and retrospective study that includes liver biopsies performed between 2015-2018. The presence and degree of fibrosis were recorded according to the METAVIR scale; F3-F4 is considered FS. Histological diagnoses and clinical data were recorded.

Results

93 HAI liver biopsies were analyzed; 80% women; average age 52 (18-82) years. Fibrosis present in 69% (F0: 29, F1: 12; F2: 10, F3: 15, F4: 27). FS at 45.2%. The diagnostic concordance (kappa index) of FS by biopsy and FIB-4 (> 3.25) was acceptable, but not for APRI (> 0.7). The ROC curve for APRI was only 0.58 and for FIB-4 0.75. With the cutoff of 0.7 the APRI had a sensitivity of 94%, but a specificity of only 10% and with the cutoff of 3.25 the FIB-4 had a sensitivity of 72% and specificity of 69%, for the diagnosis of FS.

Conclusion

In HAI the usefulness of NIT fibrosis evaluation using APRI and FIB-4 was scarce. FIB-4 could be more useful, but liver biopsy remains important for staging and prognosis.

El Texto completo está disponible en PDF
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos